leadf
logo-loader
viewTissue Regenix Group PLC

Tissue Regenix says it intends to appoint Brian Phillips and Trevor Phillips (no relation) as independent non-executive directors

Alongside these appointments, the group noted that, after many years of service, Alan Miller and Randeep Grewal have notified the board of their resignation as non-executive directors with immediate effect

Tissue Regenix Group PLC -

Tissue Regenix Group PLC (LON:TRX), the regenerative medical devices company, has said it intends to appoint Brian Phillips and Trevor Phillips (no relation) as independent non-executive directors of the company.

It noted that Brian Phillips is an entrepreneurial investment professional with over 25 years' experience. He is the current principal of Ethos partners which he co-founded in 2018 to assist individuals in establishing a portfolio of assets under private equity investments.  Prior to this, he was chief investment officer at Greenhill Capital Partners Europe where he was responsible for setting up their UK business (2006-2010) and managing director of LGV Capital (2000-2006). 

The group pointed out that Trevor Phillips is the current chairman of the Board at NEPeSMO and has extensive experience in the UK and US in corporate development, M&A and operations in the pharmaceutical and life science industries including previously held positions as executive chairman of hVIVO (2017-2020), chief operating officer for Vectura Group PLC (2011-2017) and former CEO and COO of Critical Therapeutics, Inc. (2002-2008).

READ: Tissue Regenix hails significant milestone as it ships new product line to first customer

Both will be appointed to the board of Tissue Regenix following the completion of the necessary regulatory due diligence in accordance with the AIM Rules, the company said, with Brian Phillips to chair the Audit Committee and Trevor Phillips to chair the Renumeration Committee.  

Alongside these appointments, the group noted that, after many years of service, Alan Miller and Randeep Grewal have notified the board of their resignation as non-executive directors with immediate effect.

In a statement, Jonathan Glenn, interim chair of Tissue Regenix, commented: "As we focus on leveraging our operational capabilities and driving the commercialisation of our product pipelines, I am pleased to welcome Brian and Trevor to the Board who both bring a wealth of experience that will be crucial in shaping the future strategy and success of the Group.  I would like to extend my thanks to Alan and Randeep who have been highly committed Board members and have supported the Group for many years."

Quick facts: Tissue Regenix Group PLC

Price: 0.53 GBX

AIM:TRX
Market: AIM
Market Cap: £37.28 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Morning Report: FTSE 100 heads higher as markets welcome easing of restrictions

Headlines from the Proactive UK newsroom. The FTSE 100 rose 21 points to 6,957 as markets welcomed more easing of coronavirus lockdown measures across Europe despite some confusion in the UK. UK prime minister Boris Johnson, though, is being pressed for more clarity on the relaxation of UK...

on 11/5/20

2 min read